{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T22:40:54Z","timestamp":1769812854293,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Bayer Healthcare Pharmaceuticals, Germany Fondation Gonella, Lausanne, Switzerland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,2,20]]},"DOI":"10.1038\/s41416-025-03279-9","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T06:59:06Z","timestamp":1765436346000},"page":"589-597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sorafenib plus selective internal radiotherapy with 90Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8893-5240","authenticated-orcid":false,"given":"Gr\u00e9goire","family":"Berthod","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Cisarovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent A.","family":"Decosterd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Choong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Celestini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0754-3425","authenticated-orcid":false,"given":"Michel A.","family":"Cuendet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Boughdad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1429-1374","authenticated-orcid":false,"given":"John O.","family":"Prior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Meuwly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2428-5613","authenticated-orcid":false,"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Michielin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Leyvraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"3279_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12092557","volume":"12","author":"C Rodriguez-Vidal","year":"2020","unstructured":"Rodriguez-Vidal C, Fernandez-Diaz D, Fernandez-Marta B, Lago-Baameiro N, Pardo M, Silva P, et al. Treatment of Metastatic Uveal Melanoma: Systematic Review. Cancers (Basel). 2020;12:1\u201322.","journal-title":"Cancers (Basel)"},{"key":"3279_CR2","doi-asserted-by":"publisher","first-page":"5684","DOI":"10.3390\/cancers13225684","volume":"13","author":"E Rossi","year":"2021","unstructured":"Rossi E, Croce M, Reggiani F, Schinzari G, Ambrosio M, Gangemi R, et al. Uveal Melanoma Metastasis. Cancers (Basel). 2021;13:5684.","journal-title":"Cancers (Basel)"},{"key":"3279_CR3","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/archopht.119.5.670","volume":"119","author":"JKV Willson","year":"2001","unstructured":"Willson JKV, Albert DM, Diener-West M, McCaffrey L, Mo CS, Scully RE, et al. Assessment of Metastatic Disease Status at Death in 435 Patients With Large Choroidal Melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS Report No. 15. Arch Ophthalmol. 2001;119:670\u20136.","journal-title":"Arch Ophthalmol"},{"key":"3279_CR4","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1167\/iovs.03-0538","volume":"44","author":"E Kujala","year":"2003","unstructured":"Kujala E, M\u00e4kitie T, Kivel\u00e4 T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:4651\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3279_CR5","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","volume":"123","author":"M Diener-West","year":"2005","unstructured":"Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Development of Metastatic Disease After Enrollment in the COMS Trials for Treatment of Choroidal Melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005;123:1639\u201343.","journal-title":"Arch Ophthalmol"},{"key":"3279_CR6","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1136\/bjophthalmol-2020-317949","volume":"106","author":"G Garg","year":"2022","unstructured":"Garg G, Finger PT, Kivel\u00e4 TT, Simpson R, Gallie BL, Saakyan S, et al. Patients presenting with metastases: stage IV uveal melanoma, an international study. Br J Ophthalmol. 2022;106:510\u20137.","journal-title":"Br J Ophthalmol"},{"key":"3279_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1055\/s-0040-1720948","volume":"37","author":"CF Gonsalves","year":"2020","unstructured":"Gonsalves CF, Adamo RD, Eschelman DJ. Locoregional Therapies for the Treatment of Uveal Melanoma Hepatic Metastases. Semin Interv Radio. 2020;37:508\u201317.","journal-title":"Semin Interv Radio"},{"key":"3279_CR8","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","volume":"389","author":"JC Hassel","year":"2023","unstructured":"Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, et al. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2023;389:2256\u201366.","journal-title":"N Engl J Med"},{"key":"3279_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","volume":"6","author":"MJ Jager","year":"2020","unstructured":"Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, et al. Uveal melanoma. Nat Rev Dis Prim. 2020;6:24.","journal-title":"Nat Rev Dis Prim"},{"key":"3279_CR10","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1167\/iovs.09-4755","volume":"51","author":"H Yang","year":"2010","unstructured":"Yang H, Jager MJ, Grossniklaus HE. Bevacizumab Suppression of Establishment of Micrometastases in Experimental Ocular Melanoma. Invest Ophthalmol Vis Sci. 2010;51:2835\u201342.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3279_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.humpath.2016.07.012","volume":"57","author":"HE Grossniklaus","year":"2016","unstructured":"Grossniklaus HE, Zhang Q, You S, McCarthy C, Heegaard S, Coupland SE. Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth patterns. Hum Pathol. 2016;57:165\u201375.","journal-title":"Hum Pathol"},{"key":"3279_CR12","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","volume":"7","author":"SM Wilhelm","year":"2008","unstructured":"Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129\u201340.","journal-title":"Mol Cancer Ther"},{"key":"3279_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/bjc.2016.119","volume":"115","author":"F Mouriaux","year":"2016","unstructured":"Mouriaux F, Servois V, Parienti JJ, Lesimple T, Thyss A, Dutriaux C, et al. Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study. Br J Cancer. 2016;115:20\u20134.","journal-title":"Br J Cancer"},{"key":"3279_CR14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/CMR.0b013e328358b373","volume":"22","author":"A Mahipal","year":"2012","unstructured":"Mahipal A, Tijani L, Chan K, Laudadio M, Mastrangelo MJ, Sato T. A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res. 2012;22:440\u20136.","journal-title":"Melanoma Res"},{"key":"3279_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1055\/s-0043-1777712","volume":"41","author":"CF Gonsalves","year":"2024","unstructured":"Gonsalves CF. Immunoembolization for the Treatment of Uveal Melanoma Hepatic Metastases. Semin Interv Radio. 2024;41:20\u201326.","journal-title":"Semin Interv Radio"},{"key":"3279_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.hoc.2024.08.010","volume":"39","author":"DJ H\u00f6ppener","year":"2025","unstructured":"H\u00f6ppener DJ, Gr\u00fcnhagen DJ, Eggermont AMM, van der Veldt AAM, Verhoef C. An Overview of Liver Directed Locoregional Therapies. Hematol Oncol Clin North Am. 2025;39:103\u201323.","journal-title":"Hematol Oncol Clin North Am"},{"key":"3279_CR17","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20210200","volume":"95","author":"H Alexander","year":"2022","unstructured":"Alexander H, Wen D, Chu M, Han C, Hadden P, Thomas R, et al. Selective internal radiation therapy for hepatic metastases of uveal melanoma: a systematic review. Br J Radio. 2022;95:20210200.","journal-title":"Br J Radio"},{"key":"3279_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/1947601913485414","volume":"4","author":"A Munshi","year":"2013","unstructured":"Munshi A, Ramesh R. Mitogen-Activated Protein Kinases and Their Role in Radiation Response. Genes Cancer. 2013;4:401\u20138.","journal-title":"Genes Cancer"},{"key":"3279_CR19","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20180405","volume":"92","author":"C Kanthou","year":"2019","unstructured":"Kanthou C, Tozer G. Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy. Br J Radio. 2019;92:20180405.","journal-title":"Br J Radio"},{"key":"3279_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3389\/fonc.2013.00323","volume":"3","author":"N Rana","year":"2013","unstructured":"Rana N, Ju AW, Bazylewicz M, Kallakury B, He AR, Unger KR, et al. Yttrium-90 radioembolization in patients with hepatocellular carcinoma who have previously received sorafenib. Front Oncol. 2013;3:323.","journal-title":"Front Oncol"},{"key":"3279_CR21","first-page":"553","volume":"6","author":"F Winkler","year":"2004","unstructured":"Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6:553\u201363.","journal-title":"Cancer Cell"},{"key":"3279_CR22","doi-asserted-by":"publisher","first-page":"9443","DOI":"10.1158\/0008-5472.CAN-07-1473","volume":"67","author":"JP Plastaras","year":"2007","unstructured":"Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 2007;67:9443\u201354.","journal-title":"Cancer Res"},{"key":"3279_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijrobp.2010.02.064","volume":"78","author":"AW Suen","year":"2010","unstructured":"Suen AW, Galoforo S, Marples B, McGonagle M, Downing L, Martinez AA, et al. Sorafenib and radiation: a promising combination in colorectal cancer. Int J Radiat Oncol Biol Phys. 2010;78:213\u201320.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3279_CR24","first-page":"70","volume":"15","author":"D Liu","year":"2016","unstructured":"Liu D, Westcott M, Garcia-Monaco R, Abraham R, Gandhi R. Down and dirty with dosimetry. Endovasc Today. 2016;15:70\u20136.","journal-title":"Endovasc Today"},{"key":"3279_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"3279_CR26","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S\u201350S.","journal-title":"J Nucl Med"},{"key":"3279_CR27","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jchromb.2009.04.045","volume":"877","author":"A Haouala","year":"2009","unstructured":"Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, et al. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2009;877:1982\u201396.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"3279_CR28","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1365-2125.2011.03963.x","volume":"72","author":"L Jain","year":"2011","unstructured":"Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharm. 2011;72:294\u2013305.","journal-title":"Br J Clin Pharm"},{"key":"3279_CR29","doi-asserted-by":"publisher","first-page":"7320","DOI":"10.1158\/1078-0432.CCR-19-0470","volume":"25","author":"H Inaba","year":"2019","unstructured":"Inaba H, Panetta JC, Pounds SB, Wang L, Li L, Navid F, et al. Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory\/Relapsed Leukemia or Solid Tumor Malignancies. Clin Cancer Res. 2019;25:7320\u201330.","journal-title":"Clin Cancer Res"},{"key":"3279_CR30","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","volume":"71","author":"J Ricke","year":"2019","unstructured":"Ricke J, Kl\u00fcmpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71:1164\u201374.","journal-title":"J Hepatol"},{"key":"3279_CR31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bcpt.12365","volume":"116","author":"Y Li","year":"2015","unstructured":"Li Y, Gao ZH, Qu XJ. The Adverse Effects of Sorafenib in Patients with Advanced Cancers. Basic Clin Pharm Toxicol. 2015;116:216\u201321.","journal-title":"Basic Clin Pharm Toxicol"},{"key":"3279_CR32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.critrevonc.2010.11.007","volume":"80","author":"FAB Schutz","year":"2011","unstructured":"Schutz FAB, Je Y, Choueiri TK. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: A meta-analysis of clinical trials. Crit Rev Oncol Hematol. 2011;80:291\u2013300.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3279_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40262-013-0108-z","volume":"53","author":"M Fukudo","year":"2014","unstructured":"Fukudo M, Ito T, Mizuno T, Shinsako K, Hatano E, Uemoto S, et al. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. Clin Pharmacokinet. 2014;53:185\u201396.","journal-title":"Clin Pharmacokinet"},{"key":"3279_CR34","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1080\/0284186X.2020.1759826","volume":"59","author":"TA Labeur","year":"2020","unstructured":"Labeur TA, Hofsink Q, Takkenberg RB, van Delden OM, Math\u00f4t RAA, Schinner R, et al. The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial. Acta Oncol. 2020;59:1028\u201335.","journal-title":"Acta Oncol"},{"key":"3279_CR35","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jpba.2009.02.008","volume":"49","author":"B Blanchet","year":"2009","unstructured":"Blanchet B, Billemont B, Cramard J, Benichou AS, Chhun S, Harcouet L, et al. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal. 2009;49:1109\u201314.","journal-title":"J Pharm Biomed Anal"},{"key":"3279_CR36","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8:198.","journal-title":"Signal Transduct Target Ther"},{"key":"3279_CR37","doi-asserted-by":"publisher","first-page":"14888","DOI":"10.1073\/pnas.96.26.14888","volume":"96","author":"M Streit","year":"1999","unstructured":"Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P, et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA. 1999;96:14888\u201393.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3279_CR38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jvir.2013.10.030","volume":"25","author":"DR Carpizo","year":"2014","unstructured":"Carpizo DR, Gensure RH, Yu X, Gendel VM, Greene SJ, Moore DF, et al. Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres. J Vasc Inter Radio. 2014;25:297\u2013306.","journal-title":"J Vasc Inter Radio"},{"key":"3279_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-016-0236-1","volume":"6","author":"CE Rosenbaum","year":"2016","unstructured":"Rosenbaum CE, van den Hoven AF, Braat MN, Koopman M, Lam MG, Zonnenberg BA, et al. Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response. EJNMMI Res. 2016;6:92.","journal-title":"EJNMMI Res"},{"key":"3279_CR40","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jvir.2016.03.043","volume":"27","author":"RJ Lewandowski","year":"2016","unstructured":"Lewandowski RJ, Andreoli JM, Hickey R, Kallini JR, Gabr A, Baker T, et al. Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib. J Vasc Inter Radio. 2016;27:1329\u201336.","journal-title":"J Vasc Inter Radio"},{"key":"3279_CR41","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1042\/bj3260709","volume":"326","author":"PJ Hogg","year":"1997","unstructured":"Hogg PJ, Hotchkiss KA, Jim\u00e9nez BM, Stathakis P, Chesterman CN. Interaction of platelet-derived growth factor with thrombospondin 1. Biochem J. 1997;326:709\u201316.","journal-title":"Biochem J"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03279-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03279-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03279-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:03:26Z","timestamp":1769774606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03279-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,20]]}},"alternative-id":["3279"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03279-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The trial was approved by the local institutional ethics committee (CER-VD\/ Reference number 2013DR1073). Patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}